{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.7","upperLimit":"85.3","value":"62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Progression free survival (PFS) defined as the time from treatment initiation to disease progression, relapse or death due to any cause, which ever comes first, will be described with Kaplan Meier curve.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"One ARG1-vaccine every third week for 45 weeks.\n\nARG1-18,19,20: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide","id":"OG000","title":"ARG1-18,19,20 Peptide Vaccine"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"0 - 75 weeks","title":"4.Progression Free Survival","type":"SECONDARY","unitOfMeasure":"days"}